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ABSTRACT
Background. Near-infrared (NIR) ﬂuorescent sentinel
lymph node (SLN) mapping in breast cancer requires
optimized imaging systems and lymphatic tracers.
Materials and Methods. A small, portable version of the
FLARE imaging system, termed Mini-FLARE, was
developed for capturing color video and two semi-inde-
pendent channels of NIR ﬂuorescence (700 and 800 nm) in
real time. Initial optimization of lymphatic tracer dose was
performed using 35-kg Yorkshire pigs and a 6-patient pilot
clinical trial. More reﬁned optimization was performed in
24 consecutive breast cancer patients. All patients received
the standard of care using
99mTechnetium-nanocolloid and
patent blue. In addition, 1.6 ml of indocyanine green
adsorbed to human serum albumin (ICG:HSA) was injec-
ted directly after patent blue at the same location. Patients
were allocated to 1 of 8 escalating ICG:HSA concentration
groups from 50 to 1000 lM.
Results. The Mini-FLARE system was positioned easily
in the operating room and could be used up to 13 in. from
the patient. Mini-FLARE enabled visualization of lym-
phatic channels and SLNs in all patients. A total of 35
SLNs (mean = 1.45, range 1–3) were detected: 35 radio-
active (100%), 30 blue (86%), and 35 NIR ﬂuorescent
(100%). Contrast agent quenching at the injection site and
dilution within lymphatic channels were major contributors
to signal strength of the SLN. Optimal injection dose of
ICG:HSA ranged between 400 and 800 lM. No adverse
reactions were observed.
Conclusions. We describe the clinical translation of a new
NIR ﬂuorescence imaging system and deﬁne the optimal
ICG:HSA dose range for SLN mapping in breast cancer.
Sentinel lymph node (SLN) mapping, as introduced for
the management of breast cancer by Giuliano et al., is
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axilla.
1,2 In general, a combination of radioactive colloid
and blue dye is used. However, this exposes patients and
caregivers to ionizing radiation, and blue dyes cannot be
seen through skin and fatty tissue. Nonetheless, in recent
trials, SLN identiﬁcation rates of 95–97% are achieved
when using this combination, and use of only 1 agent
results in signiﬁcantly lower identiﬁcation rates.
3–6
Recent preclinical and clinical data have demonstrated
that near-infrared (NIR) ﬂuorescence imaging using the
NIR ﬂuorescence agent indocyanine green (ICG) enables
real-time transcutaneous and intraoperative visualization of
lymphatic channels and detection of the SLN.
7–14 There-
fore, NIR ﬂuorescence imaging could provide an
alternative for, or an addition to, conventional techniques
used for SLN mapping. However, to date, clinical data are
lacking a direct comparison of NIR ﬂuorescence to the
combination of radioactive tracer and blue dye. Also, even
though ICG is the only ﬂuorescent agent currently avail-
able in the clinic, it is not an optimal lymphatic tracer.
Previous preclinical work has demonstrated that adsorption
of ICG to human serum albumin (HSA, complex is
ICG:HSA) increases the ﬂuorescence intensity and the
hydrodynamic diameter, thereby providing improved
detection and better retention in the SLN.
15
Recently, ﬁrst in-human clinical testing of ICG:HSA
was performed.
14 The ﬂuorescence-assisted resection and
exploration (FLARE) imaging system, developed by our
group and used in the trial, is a general-purpose optical
imaging platform that provides the surgeon with 2 inde-
pendent NIR ﬂuorescence channels (centered at 700 and
800 nm) to see otherwise invisible structures within the
surgical ﬁeld.
14,16 The ﬁrst generation of FLARE was
large, expensive to build, and had a heavy imaging head
that required a specially designed articulated arm.
14 This
prevented shipment of FLARE to researchers around the
world, and therefore impeded efﬁcient scientiﬁc investi-
gation. During the ﬁrst in-human clinical testing of
FLARE, it also became apparent that contrast agents for
SLN mapping were not yet optimal. The goals of the
present study were to develop a miniaturized version of
FLARE, termed Mini-FLARE, and to determine optimal
lymphatic tracer dosing for SLN mapping in breast cancer.
METHODS
Mini-FLARE Imaging System
A detailed description of the Mini-FLARE imaging
system and in vitro characterization is provided in Sup-
plementary Data. For sterile usage in the operating room, a
0.118-in. thick acrylic splash shield having 95% optical
transmission at 800 nm was hermetically bonded to a clear
plastic drape and sterilized (Medical Technique, Inc.,
Tucson, AZ).
Preparation of Indocyanine Green Adsorbed to Human
Serum Albumin
ICG (25-mg vials) was purchased from Pulsion Medical
Systems (Munich, Germany) and was resuspended in 10 cc
of sterile water for injection to yield a 2.5-mg/ml (3.2-mM)
stock solution. Various amounts of this stock solution were
transferred to a 50-cc vial of Cealb (20% human serum
albumin [HSA] solution; Sanquin, Amsterdam, The Neth-
erlands) to yield ICG in HSA (ICG:HSA) at a ﬁnal
concentration of 50 lM, 100 lM, 200 lM, 400 lM,
500 lM, 600 lM, 800 lM, or 1000 lM. To obtain a ﬁnal
concentration of 800 and 1000 lM, ICG was resuspended
in 5 cc of sterile water, to yield a 6.4-mM stock solution
prior to dilution.
Preclinical Characterization
Animals were studied under the supervision of approved
institutional protocol. Female Yorkshire pigs (E.M. Par-
sons and Sons, Hadley, MA) averaging 35 kg were induced
with 4.4-mg/kg intramuscular Telazol (Fort Dodge Labs,
Fort Dodge, IA), intubated, and maintained with 2% iso-
ﬂurane (Baxter Healthcare, Deerﬁeld, IL). Vital signs were
monitored continuously. Excitation ﬂuence rate for white
light and 800-nm excitation light were 26,600 lux and 7.7
mW/cm
2, respectively. Also 100 lL of the speciﬁed
ICG:HSA solution was injected intradermally. ICG con-
centration of the ICG:HSA complex was systematically
increased from 10 to 500 lM to explore the counteracting
effects of NIR ﬂuorophore quenching at the injection site
and NIR ﬂuorophore dilution within the lymphatic
channels.
Dose-Optimization Clinical Trial
Details of the initial 6-patient pilot study of breast
cancer SLN mapping using ICG:HSA and Mini-FLARE is
provided in the Supplementary Data. The 24-patient dose-
escalation clinical trial was approved by the Medical Ethics
Committee of the Leiden University Medical Center and
was performed in accordance with the ethical standards of
the Helsinki Declaration of 1975. All patients who had
planned to undergo a SLN procedure for invasive breast
cancer or extensive high-risk carcinoma in situ were eli-
gible for participation in the study. Patients had clinically
negative axillary nodes as assessed by palpation and
ultrasonography. Exclusion criteria were pregnancy,
2484 J. S. D. Mieog et al.lactation, or an allergy to iodine, shellﬁsh, or indocyanine
green.
A total of 24 consecutive patients were included. All
patients gave informed consent and were anonymized.
Patients received the standard-of-care SLN procedure. For
our institution, this implies 1 periareolar injection of
approximately 100 MBq
99mTechnetium-nanocolloid
(mean ± S.D. = 99.6 ± 5.8 MBq) the day before surgery.
Before the start of the operation, 1 ml of patent blue V was
injected peritumorally or periareolarly. Choice of the
injection site was left to the surgeon. Directly after patent
blue injection, 1.6-ml ICG:HSA was administered as 4
injections at the same location as the patent blue injections.
After surgical scrub and sterile covering of the operation
ﬁeld, NIR ﬂuorescence imaging was performed with the
imaging head of the Mini-FLARE at approximately 30-cm
distance to the surgical ﬁeld.
The surgical technique consisted of percutaneous
assessment of NIR ﬂuorescent signal in the breast and the
axilla prior to skin incision. The location and length of the
axillary skin incision was determined by the surgeon.
Assessment of the surgical ﬁeld using NIR ﬂuorescence
was applied continuously throughout the SLN procedure
and surgical exploration. If the SLN was not easily
detected by NIR ﬂuorescence, the gamma probe was used
to provide direction for surgical exploration. Camera
exposure was between 5 and 250 ms as indicated. A SLN
exhibiting a signal-to-background ratio (SBR) C 1.1 in situ
was considered positive by NIR ﬂuorescence. Background
was chosen as an area within the surgical ﬁeld, directly
adjacent (within 1–2 cm) to the SLN.
Routine histopathological frozen analysis of SLNs was
performed during surgery. If the patient participated in the
After Mapping of the Axilla Radiotherapy or Surgery
(AMAROS) trial and was randomized to the radiotherapy
arm, no intraoperative frozen analysis was performed. SLNs
were ﬁxed in formalin and embedded in parafﬁn for routine
hematoxylin, eosin, and immunohistopathological staining
for AE1/AE3 at 3 levels, with an interval of 150–250 lm,
according to the Dutch guidelines forSLN analysis. Patients
underwent an axillarylymph node dissectionif the SLN was
found to contain metastases, except for those patients who
participatedintheradiotherapyarmoftheAMAROStrial.If
isolated tumor cells (ITCs) were found (\0.2 mm), no
axillary lymph node dissection was performed.
Statistical Analysis
For statistical analysis, SPSS statistical software pack-
age (Version 16.0, Chicago, IL) was used. Graphs were
generated using GraphPad Prism Software (Version 5.01,
La Jolla, CA). To compare the SBR between concentration
groups, a one-way analysis of variance (ANOVA) was
performed with pairwise comparison with least squares
difference (LSD) adjustment for multiple testing. When
the assumption of homogeneity of variance was violated
(Levene’s test), a log10 transformation was applied. All
statistical tests were 2-tailed and P\.05 was considered
signiﬁcant.
RESULTS
Design of the Mini-FLARE Imaging System
and In Vitro Characterization
The Mini-FLARE imaging system (Fig. 1a) is com-
posed of a small portable electronics cart and a
counterweighted pole stand that supports the imaging head.
Unlike FLARE, Mini-FLARE uses a ﬂexible gooseneck
arm, which permits positioning of the imaging head at
extreme angles virtually anywhere over the surgical ﬁeld.
The only consumable for Mini-FLARE is a specially
designed acrylic splash plate that is hermetically sealed to a
plastic drape. Using sterile technique, the shield/drape is
inserted into the imaging head, locked into place, and the
drape is unfolded to encase the imaging head and imaging
system pole stand (Fig. 1b). Optical light paths for white
light (i.e., color video images) and the 2 semi-independent
NIR ﬂuorescence channels, 1 centered at 700 nm emission
and the other at 800 nm emission, are shown in Fig. 1c.
Technical speciﬁcations of Mini-FLARE are detailed in
Table 1. Of note, the working distance is up to 13 in. away
from the patient, with ﬁeld-of-view adjustable from 4.7 in.
(12 cm) to 2 in. (5 cm) simply by moving the device
toward or away from the surgical ﬁeld. The cart occupies a
volume of only 9.7 ft
3, and weighs only 272 lb. A 6-pedal
footswitch and autofocus circuit permit hands-free opera-
tion. The cost of all parts is *$40,000.
Preclinical Optimization of NIR Fluorescent Lymphatic
Tracers
Our group has previously reported that ICG (and
ICG:HSA) exhibits intense quenching (i.e., reduction of
ﬂuorescence emission) as its concentration is increased.
15
That is, increasing concentration actually decreases ﬂuo-
rescence, so there would theoretically be no beneﬁt to
injecting high concentration for SLN mapping. This effect
is demonstrated vividly in Fig. 2a (left), where the injec-
tion site becomes dramatically less ﬂuorescent as
concentration increases. As a general rule, if the concen-
tration is high enough to see green color at the injection
site, ICG ﬂuorescence is severely quenched.
Importantly, we have recently discovered that dilution
of the injected NIR ﬂuorophore as it travels through the
lymphatic system and mixes with lymph counteracts the
NIR Fluorescent Sentinel Node Mapping 2485effect of quenching and results in signal in the SLN that
increases with concentration, even when the injection site
is barely ﬂuorescent (Fig. 2a, right). This suggests that
there will be an ‘‘optimal’’ concentration of injected NIR
ﬂuorophore such that ﬁnal signal in the SLN is as high as
possible.
Optimization of ICG:HSA Dose in Women Undergoing
SLN Mapping for Breast Cancer
This study aimed to test the feasibility of NIR ﬂuores-
cence in SLN detection, using ICG:HSA and the
Mini-FLARE, in direct comparison with the conventional
lymphatic tracers radiocolloid and patent blue. A total of
24 consecutive breast cancer patients underwent standard-
of-care SLN mapping with the addition of preoperative
ICG:HSA injection and subsequent intraoperative NIR
ﬂuorescence imaging. Patient and tumor characteristics are
provided in Table 2. Use of the Mini-FLARE during sur-
gery did not interfere with the standard of care. Average
time between ICG:HSA injection and skin incision was
16 ± 3 min (Table 3). In all patients (N = 24), NIR ﬂuo-
rescence imaging enabled visualization of the SLN
(Fig. 3). A total of 35 SLNs were identiﬁed, which were all
radioactive and NIR ﬂuorescent (Table 3). There were 5
SLNs from 4 patients that did not have blue staining from
patent blue. In all patients, the NIR ﬂuorescence signal in
the SLN was detected before patent blue. Average time
between skin incision and resection of the ﬁrst SLN was
17 ± 5 min. After all nodes detected using NIR ﬂuores-
cence were resected, the axilla was systematically
inspected for any remaining radioactivity. No additional
radioactive nodes were identiﬁed that were not detected by
NIR ﬂuorescence. No adverse reactions associated with the
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FIG. 1 The Mini-FLARE portable near-infrared ﬂuorescence imag-
ing system. a Imaging system, composed of electronics/monitor cart
and counterweighted imaging system pole. b Sterile drape/shield
attached to the imaging head with other major parts identiﬁed.
c Excitation and emission light paths, and ﬁltration for the Mini-
FLARE imaging system. DM, 650 nm dichroic mirror
2486 J. S. D. Mieog et al.use of ICG:HSA or the Mini-FLARE occurred. Two
patients experienced a wound infection requiring antibiot-
ics, and one patient underwent surgical re-exploration
because of an expanding hematoma following axillary
lymph node dissection (Table 3).
A second objective of this trial was to determine the
optimal concentration of injected ICG:HSA for NIR ﬂuo-
rescence SLN mapping, i.e., which concentration provides
the highest SBR in the SLN. Because ICG and ICG:HSA
exhibit intense quenching as their concentrations are
increased (typically above 50 lM), there would theoreti-
cally be no advantage to injecting higher doses of
ICG:HSA. However, dilution of the lymphatic tracer
occurs upon injection in the breast and uptake by the
lymphatic system counteracting the quenching effect. To
assess the relationship between the concentration of
injected NIR ﬂuorescent lymphatic tracer and ﬁnal SBR in
the SLN, patients were allocated to 8 ICG:HSA concen-
tration groups ranging from 50 to 1000 lM. The
concentration of ICG:HSA inﬂuenced the SBR and showed
a normal distribution (Fig. 2b). The variances of the con-
centration groups were not equal (Levene’s test, P = .02).
A log10 transformation of the data could account for part
of the unequal variances (Levene’s test, P = .05). A 1-way
ANOVA with pairwise comparison with LSD adjustment
for multiple comparison showed that the SBRs of the 400,
TABLE 1 Mini-FLARE imaging system speciﬁcations
Category/speciﬁcation Description
Physical
Size Mobile cart: 24 in. W 9 24 in. D 9 29 in. H; mast height: 76.5 in.
Weight Cart: 272 lb, including all electronics
Arm: 95 lb, including, stand, gooseneck, and imaging head
Imaging head: 8.8 lb
Arm and stand Flexible arm; reach: 27–64 in. from ﬂoor, 42 in. from center
of stand. Center of stand up to 11 linear ft from cart
Electrical
Voltage and plug 120 V AC, 60 Hz; single NEMA 5–15 120 V/15 A AC plug
Current 5 A max
Grounding Isolation transformer for all components; redundant chassis grounding
Leakage current \300 lA (per AAMI/IEC No. 60601)
Sterility
Shield Disposable acrylic shield with C95% transmission
Drape Disposable, custom-ﬁt plastic drape bonded to shield
Light source
Housing Anodized aluminum with integrated liquid cooling
Elements Custom 25-mm circular LED arrays w/integrated linear drivers
Electronics Custom control board with embedded microcontroller
Fluence rates 26,600 lux white light (400–650 nm), 1.08 mW/cm
2 of 700 nm (656–678 nm) excitation l
ight, 7.70 mW/cm
2 of 800 nm (745–779 nm) excitation light
Optics
Working distance 4–13 in. (10–32 cm) from patient (reverse telephoto)
Field-of-view 12 cm W 9 9 cm H at 13 in. working distance
Emission/reﬂectance channels Color video (400–650 nm), 700 nm ﬂuorescence (689–725 nm), 800 nm ﬂuorescence (800–848 nm),
all with simultaneous acquisition
Pixel resolution 640 9 480 for each camera
System resolution 320 9 320 lm( x, y)
Display refresh Up to 15 Hz simultaneous acquisition on both cameras
NIR exposure time Adjustable from 100 lst o8s
Hands-free
Optics Automatic focus
Control 6-pedal footswitch
Monitors
Number 3 cart-mounted 20 in.: 2 for operator and 1 for surgeon
NIR Fluorescent Sentinel Node Mapping 2487500, 600, and 800 lM concentration groups were signiﬁ-
cantly higher than of the 50, 100, 200, and 1000 lM
concentration groups (200 vs. 400, P = .001; 200 vs. 500,
P = .001; 200 vs. 600, P\.0001; 200 vs. 800, P = .001;
1000 vs. 400, P\.0001; 1000 vs. 500, P\.0001; 1000
vs. 600, P\.0001; 1000 vs. 800, P\.0001). The SBRs of
the 400, 500, 600, and 800 lM concentration groups were
not signiﬁcantly different, although a trend was found
favoring the 600 lM concentration group (500 vs. 600,
P = .06). The decline of the SBR in the 1000 lM con-
centration group was caused by decreased NIR
ﬂuorescence signal of the SLN (800 vs. 1000, P = .001),
which suggests that quenching of ICG indeed occurred in
the SLN.
DISCUSSION
Near-infrared (NIR) ﬂuorescent light in the wavelength
range of 700–900 nm is invisible to the human eye. It is also
capable of penetrating millimeters into living tissue and is
not obscured by autoﬂuorescence. For these reasons, NIR
ﬂuorescent light is ideal for image-guided surgery. Indeed,
several NIR ﬂuorescence surgical imaging systems are
already FDA approved or are in the process of obtaining
approval (reviewed in Ref.
17). The Mini-FLARE camera
system used in this study is capable of displaying NIR
ﬂuorescence signal in relation to the surgical anatomy and
illuminates the surgical ﬁeld with white light. This enabled
thesurgeontoperformsurgery under directimage guidance.
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FIG. 2 Optimization of
ICG:HSA dose as a function of
the complex trade-off between
ﬂuorescence quenching at the
injection site and dilution of
ﬂuorophore in lymphatic
channels. a Preclinical studies
in Yorkshire pigs. Subcutaneous
injection sites (left; white
arrows) showing quenching and
resected SLNs (right) showing
NIR ﬂuorophore dilution for
increasing concentrations of
ICG:HSA. For each are
displayed color video (left
columns) and 800 nm NIR
ﬂuorescence (right columns)
images obtained using 760 nm
excitation light at 7.7 mW/cm
2.
All camera exposure times were
45 ms. Data are representative
of n = 3 pigs. b Optimization of
ICG:HSA dose for breast cancer
SLN mapping: Signal-to-
background ratio (mean ± SD)
of the SLNs (ordinate) as a
function of injected dose of
ICG:HSA (abscissa) in women
undergoing SLN mapping for
breast cancer. Statistical
comparisons are: 200 vs.
400 lM, P = .001; 200 vs.
500 lM, P = .001; 200 vs.
600 lM, P\.0001; 200 vs.
800 lM, P = .001; 1000 vs.
400 lM, P\.0001; 1000 vs.
500 lM, P\.0001; 1000 vs.
600 lM, P\.0001; 1000 vs.
800 lM, P\.0001. The SBRs
of the 400, 500, 600, and
800 lM concentration groups
were not signiﬁcantly different,
although a trend was found
favoring the 600 lM
concentration group (500 vs.
600, P = .06)
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offers the advantages of real-time, continuous, high-reso-
lution, and high-sensitivity detection of SLNs, without the
need for ionizing radiation. Because NIR light is invisible,
there is no staining of the surgical ﬁeld as with blue dyes,
and the class of chemicals in which ICG belongs has a
remarkable safety record in humans. ICG:HSA adds
approximately $150 to the cost of a case, but if future
studies show that the blue dye and/or Tc-99 m sulfur col-
loid can be eliminated when using NIR ﬂuorescence, a
much larger savings will offset this cost. And, the surgeon
can perform the injection procedure only minutes before
SLN identiﬁcation and resection. Although a technologist
was used in this ﬁrst in-human study, Mini-FLARE is
equipped with hands-free operation and there is virtually
no learning curve because unlike other SLN techniques, the
lymphatic tracer can be visualized in real-time throughout
the procedure.
An important objective of the study was to optimize NIR
ﬂuorescent contrast agent dose for breast cancer SLN
mapping. The only clinically available NIR ﬂuorescent
lymphatic tracer, albeit approved for other indications, is
ICG.
7,11,13,18,19 We have previously proposed simple
TABLE 2 Patient and tumor characteristics
Characteristic N %
Age (median, range) 59.5 (33–81)
Menopausal state
Premenopausal 5 21
Postmenopausal 19 79
Body mass index (median, range) 25 (18–38)
Skin type
II 4 17
III 20 83
Previous breast surgery
a 31 3
Multifocality 4 17
Tumor side
Left 14 58
Right 10 42
Tumor localization
Central 5 21
Lower inner 1 4
Lower outer 1 4
Upper inner 6 25
Upper outer 11 46
Type of operation
Ablation 9 38
Wide local excision 15 63
Pathological tumor size (median, range) 15 (3–35)
Histological type
Inﬁltrating ductal adenocarcinoma 18 75
Inﬁltrating lobular adenocarcinoma 2 8
Ductal carcinoma In Situ 4 17
Histological grade
I3 1 3
II 13 54
III 8 33
Receptor status
b
ER ? HER2- 16 67
ER ? HER2? 31 3
ER - HER2- 14
Missing
c 41 7
a Previous breast surgery: silicone breast implantation, breast
reduction, and re-excision
b HER2 status was determined using the chromogenic in situ
hybridization (CISH) kit of Zymed (Invitrogen, Carlsbad, CA)
c Not applicable in 4 patients with ductal carcinoma in situ
TABLE 3 SLN identiﬁcation results
Characteristic N %
Injection site patent blue and ICG:HSA
Periareolar 20 83
Peritumoral 4 17
SLN detection
Number of SLNs identiﬁed 35
Average number of SLNs identiﬁed (range) 1.45 (1–3)
Method of detection
Radioactive 35 100
Blue 30 86
Near-infrared ﬂuorescence 35 100
Average time between injection of ICG:HSA
and skin incision (SD) (minutes)
16 ± 3
Average time between skin incision and SLN
resection (SD) (minutes)
17 ± 5
Histology
Negative 26 74
Isolated tumor cells 3 9
Micrometastases 0 0
Macrometastases 6 17
Axillary treatment
None 16 67
Axillary lymph node dissection 5 21
Axillary radiotherapy 3 13
Complications
No 21 87
Yes 3
a 13
ICG:HSA indocyanine green adsorbed to human serum albumin, SLN
sentinel lymph node, SD standard deviation
a Two patients experienced postoperative wound infection requiring
treatment with antibiotics, and one patient underwent surgical
re-exploration because of an expanding hematoma following axillary
lymph node dissection
NIR Fluorescent Sentinel Node Mapping 2489mixing of ICG and HSA (ICG:HAS) prior to injection
because ICG is a small molecule and like blue dyes can
pass through SLNs and exhibit a relatively low quantum
yield in aqueous environments.
14,15 Indeed, the product
insert for ICG notes that it rapidly binds albumin when
injected intravenously, so premixing merely improves
kinetics. Importantly, though, premixing increases quan-
tum yield (i.e., brightness) 3-fold and also results in a ﬁnal
hydrodynamic diameter (*7 nm) that is better retained in
the SLN.
15
NIR ﬂuorescent signal in the SLN is a complex function
of the concentration of the injected NIR lymphatic tracer,
the distance between the injection site and the SLN, the
volume of ultraﬁltrate within the lymphatic channels
encountered by the NIR ﬂuorophore, and retention of the
NIR ﬂuorophore by the SLN. Of these, only the injection
concentration can be controlled. Our study suggested that
an optimal ICG:HSA concentration is in the range 400 and
800 lM. In the 1000-lM concentration group, the ﬂuo-
rescence intensity of the SLN and the SBR decreased
rapidly, most likely due to quenching. Furthermore, since
lymphatic vessels could be visualized percutaneously and
directly after incision, particularly in the optimal dose
range groups, a more efﬁcient identiﬁcation of SLNs was
facilitated. This is of particular beneﬁt for lymph nodes
located deeper in the axilla, which exceed the 1–2 cm
depth limit of the technology. These nodes could often be
located by following the NIR ﬂuorescent signal of the
afferent lymphatic tract, as demonstrated in Supplementary
Video 1.
The accuracy of SLN identiﬁcation using ICG ﬂuores-
cence was similar to that using conventional radioisotope
scanning, as both techniques identiﬁed all SLNs and no
additional ﬂuorescent lymph nodes were identiﬁed. How-
ever, blue dye identiﬁcation was not successful in 5 of 35
(14%) SLNs. These results suggest that patent blue staining
can be replaced by NIR ﬂuorescence using ICG:HSA.
Replacing patent blue has the additional advantage of
absent tattooing of the breast and visual alteration of the
surgical ﬁeld. Moreover, the intrinsic dark color of patent
blue dye can obscure the ﬂuorescence intensity of any
ﬂuorescent lymphatic tracer. Indeed, in vitro tests using a
ﬁxed ICG:HSA concentration showed that addition of
patent blue dye decreased NIR ﬂuorescence of ICG:HSA
(data not shown). An as yet unanswered question is whe-
ther radioisotope scanning can be omitted from the SLN
procedure. A larger trial to address whether NIR ﬂuores-
cence imaging alone can replace blue dyes and/or
radiocolloids is ongoing.
In summary, this study demonstrated feasibility and
accuracy of NIR ﬂuorescence imaging using ICG:HSA and
the Mini-FLARE imaging system for SLN mapping in
breast cancer patients. The optimal dose of injected
ICG:HSA lies between 400 and 800 lM and can be chosen
based on local preparation preferences. For example, in the
United States, a dose of 500 lM is most convenient since it
requires minimal manipulation of albumin volumes.
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